Recalls for Blood

0.9 Percent Sodium Chloride Injection, USP, 250 mL VisIV Container by Hospira: Recall - Particulate Matter
03/06/2015 Medical Recall

Injected particulate material may result in localized inflammation, phlebitis, allergic reaction, granuloma formation or microembolic effects, and/or low-level allergic response.

  • Company:
    Hospira
0.9 Percent Sodium Chloride Injection, USP, 250 mL by Hospira : Recall - Particulate Matter
01/23/2015 Medical Recall

Injected particulate material may result in local inflammation, phlebitis, and/or low-level allergic response.

  • Company:
    Hospira
Heparin Sodium, 1,000 USP Heparin Units/500 mL (2 USP Heparin Units/mL), In 0.9 percent Sodium Chloride Injection, 500 mL by Hospira: Recall - Particulate Matter
09/12/2014 Medical Recall

Risk of injected particulate material which may result in local inflammation, phlebitis, and/or low-level allergic response.

  • Company:
    Hospira
CUBICIN (daptomycin for injection) 500 mg in 10 mL Single Use Vials: Recall - Foreign Particulate Matter
08/09/2014 Medical Recall

Administration of particulate matter poses a potential safety risk to patients such as a thromboembolism or a life-threatening pulmonary embolism.

  • Company:
    Cubist Pharmaceuticals
Cubicin (daptomycin for injection) 500 mg in 10 mL Single Use Vials: Recall - Presence Of Particulate Matter
08/08/2014 Medical Recall

The administration of a glass particulate poses a potential safety risk to patients such as a thromboembolism or a life-threatening pulmonary emboli.

  • Company:
    Cubicin
CUBICIN (daptomycin for injection) by Cubist Pharmaceuticals: Recall - Presence of Particulate Matter
04/18/2014 Medical Recall

Potential risk of thromboembolism, pulmonary emboli, phlebitis, mechanical block of the capillaries or arterioles, activation of platelets, subsequent generation of microthrombi, and emboli.

  • Company:
    Cubicin
Covidien Monoject Prefill Flush Syringes: Recall - Not Subjected To AutoClave Sterilization Process Or Mismatched Syringe Tip Cap, Syringe Label, Filled Volume And Wrapper
08/20/2013 Medical Recall

Health risk of life-threatening infection to the blood stream or patency of device may not be maintained and clotting may occur.

  • Company:
    Covidien
Hydroxyethyl Starch Solutions: FDA Safety Communication - Boxed Warning on Increased Mortality and Severe Renal Injury and Risk of Bleeding
06/24/2013 Medical Recall

FDA has analyzed recent data indicating increased mortality and renal injury in critically ill adult patients who are treated with HES solutions. Posted 06/24/2013

  • Category
    Blood